Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function

被引:300
作者
Hayward, CPM
Harrison, P
Cattaneo, M
Ortel, TL
Rao, AK
机构
[1] McMaster Univ, Med Ctr, Hamilton Hlth Sci Corp, Hamilton, ON L8N 3Z5, Canada
[2] Hamilton Reg Lab Med Program, Hamilton, ON, Canada
[3] Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England
[4] Churchill Hosp, Thrombosis Unit, Oxford OX3 7LJ, England
[5] Univ Milan, DMCO, Osped San Paolo, Unita Ematol & Trombois, Milan, Italy
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19140 USA
关键词
D O I
10.1111/j.1538-7836.2006.01771.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Closure time (CT), measured by platelet function analyzer (PFA-100((R))) device, is now available to the clinical laboratory as a possible alternative or supplement to the bleeding time test. Aim: On behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH-SSC), a working Group was formed to review and make recommendations on the use of the PFA-100 CT in the evaluation of platelet function within the clinical laboratory. Methods: The Medline database was searched to review the published information on the PFA-100 CT in the evaluation of platelet disorders and platelet function. This information, and expert opinion, was used to prepare a report and generate consensus recommendations. Results: Although the PFA-100 CT is abnormal in some forms of platelet disorders, the test does not have sufficient sensitivity or specificity to be used as a screening tool for platelet disorders. A role of the PFA-100 CT in therapeutic monitoring of platelet function remains to be established. Conclusions: The PFA-100 closure time should be considered optional in the evaluation of platelet disorders and function, and its use in therapeutic monitoring of platelet function is currently best restricted to research studies and prospective clinical trials.
引用
收藏
页码:312 / 319
页数:8
相关论文
共 94 条
[1]   Antiplatelet effect of aspirin in patients with cerebrovascular disease [J].
Alberts, MJ ;
Bergman, DL ;
Molner, E ;
Jovanovic, BD ;
Ushiwata, I ;
Teruya, J .
STROKE, 2004, 35 (01) :175-178
[2]   HEMATOCRIT AND BLEEDING-TIME - AN UPDATE [J].
ANAND, A ;
FEFFER, SE .
SOUTHERN MEDICAL JOURNAL, 1994, 87 (03) :299-301
[3]   Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease [J].
Andersen, K ;
Hurlen, M ;
Arnesen, H ;
Seljeflot, I .
THROMBOSIS RESEARCH, 2002, 108 (01) :37-42
[4]   GPVI levels in platelets: relationship to platelet function at high shear [J].
Best, D ;
Senis, YA ;
Jarvis, GE ;
Eagleton, HJ ;
Roberts, DJ ;
Saito, T ;
Jung, SM ;
Moroi, M ;
Harrison, P ;
Green, FR ;
Watson, SP .
BLOOD, 2003, 102 (08) :2811-2818
[5]  
Böck M, 1999, BRIT J HAEMATOL, V106, P898
[6]   Duration of increased bleeding tendency after cessation of aspirin therapy [J].
Cahill, RA ;
McGreal, GT ;
Crowe, BH ;
Ryan, DA ;
Manning, BJ ;
Cahill, MR ;
Redmond, HP .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2005, 200 (04) :564-573
[7]   Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100®) [J].
Carcao, MD ;
Blanchette, VS ;
Stephens, D ;
He, LJ ;
Wakefield, CD ;
Butchart, S ;
Christie, DJ ;
Rand, ML .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (04) :961-964
[8]  
Carcao MD, 1998, BRIT J HAEMATOL, V101, P70
[9]   Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems [J].
Cariappa, R ;
Wilhite, TR ;
Parvin, CA ;
Luchtman-Jones, L .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (06) :474-479
[10]   Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion [J].
Cattaneo, M ;
Lecchi, A ;
Agati, B ;
Lombardi, R ;
Zighetti, ML .
THROMBOSIS RESEARCH, 1999, 96 (03) :213-217